Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 13/20 | 0.72 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.72 |
| ▸ | HTR2A | P28223 | 3/20 | 0.59 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31415127 | 0.87 | GPR84 (0.72) | MPOGPR84HTR2AHTR2CHTR1A | |
| SCHEMBL18383118 | 0.84 | GPR84 (1.00) | MPOGPR84HTR2ATRPM8HTR2C | |
| SCHEMBL30913603 | 0.84 | GPR84 (1.00) | MPOGPR84HTR2ATRPM8HTR2C | |
| SCHEMBL30482437 | 0.84 | GPR84 (1.00) | MPOGPR84HTR2ATRPM8HTR2C | |
| SCHEMBL2404396 | 0.84 | MPO (1.00) | MPOGPR84HTR2ATRPM8HTR2C | |
| SCHEMBL13973054 | 0.84 | MPO (0.74) | MPOGPR84HTR2ATRPM8HTR2C | |
| SCHEMBL13958836 | 0.83 | GPR84 (0.61) | MPOGPR84HTR2ATRPM8HTR2C | |
| SCHEMBL5238410 | 0.81 | MPO (1.00) | MPOGPR84SLC6A4 | |
| SCHEMBL23456044 | 0.81 | HTR1D (0.61) | MPOGPR84HTR2AHTR2CHTR1A | |
| SCHEMBL8297901 | 0.81 | GPR84 (0.73) | MPOGPR84HTR2ATRPM8HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119332255-A | Electrochemical synthesis method of arundone derivatives | 云南师范大学 | 2025-01-21 | — | — | CN | disclosed |
| EP-3939968-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | Medicinal Bioconvergence Research Center (KR) | 2022-01-19 | — | — | EP | disclosed |
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CUBIST PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-7408025-B2 | Lipopeptides as antibacterial agents | CUBIST PHARMACEUTICALS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CLPTM1, NGLY1, VIP | MPO 925/4885GPR84 2944/4885HTR2A 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.